NEW YORK (GenomeWeb News) - Agilent Technologies will manufacture siRNAs for Calando, Calando said today.
 
Agilent will manufacture the active siRNA component for Calando’s targeted siRNA anti-cancer therapeutic, CALAA01. Agilent will also provide Investigational New Drug-enabling services such as pharmacokinetic and toxicity studies and cGMP production.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.